Olanib 50 mg (Capsule)
Unit Price: ৳ 800.00 (1 x 112: ৳ 89,600.00)
Strip Price: ৳ 89,600.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Olaparib |
| Company | Everest pharmaceuticals ltd |
| Also available as |
Indications
- Breast Cancer treatment as monotherapy
- Treatment for deleterious BRCA-mutated (gBRCAm) metastatic breast cancer
- Treatment for HER2-negative metastatic breast cancer
- Previous chemotherapy in neoadjuvant, adjuvant or metastatic setting
- Maintenance treatment for platinum sensitive relapsed high-grade epithelial ovarian cancer
- Tumor growth inhibition
- DNA repair inhibition
Pharmacology
- Inhibition of PARP1, PARP2, and PARP3 enzymes
- Cellular homeostasis regulation
- DNA transcription regulation
- Cell cycle regulation
- Tumor growth inhibition
- Cytotoxicity induction
- Plasma concentration and distribution
- Metabolism and excretion
Dosage & Administration
- Oral administration
- Recommended dose: 400 mg twice daily
- Dose adjustments for adverse reactions
- Dose adjustments for CYP3A inhibitors
- Dose adjustments for renal impairment
- Pediatric use safety and efficacy
Interaction
- Potentiation of myelosuppressive toxicity
- CYP3A inhibitors' impact on plasma concentrations
- CYP3A inducers' impact on plasma concentrations
Contraindications
- Hypersensitivity to the drug or its ingredients
Side Effects
- Common serious adverse reactions
- Anemia
- Dermatitis
- Neutrophil count decrease
- Platelet count decrease
- Discontinuation due to adverse events
Pregnancy & Lactation
- Fetal harm potential
- Embryo-fetal toxicity
- Excretion in human milk
Precautions & Warnings
- Myelodysplastic Syndrome/Acute Myeloid Leukemia risk
- Pneumonitis risk
- Hematological toxicity monitoring
- Pneumonitis symptom monitoring
Overdose Effects
- No specific treatment
- General supportive measures
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Dry storage below 30°C, protect from light